Roche received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Ronapreve (casirivimab and imdevimab), for the treatment of mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act.    The approval is based on results from the global phase III REGN-COV 2067 study in high-risk non-hospitalized patients with COVID-19, which showed that casirivimab an...